ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage immuno-oncology company, announced that its CEO, Jaume Pons, Ph.D., will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 10:30 am ET. The presentation will focus on ALX Oncology’s lead product candidate, evorpacept, which targets the CD47 checkpoint pathway and shows promise in treating various malignancies. Investors can access the live webcast and replay via ALX Oncology’s website.
Positive
- None.
Negative
- None.
News Market Reaction – ALXO
In the trading session that priced this news, ALXO declined 5.62%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will virtually present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 am ET.
A live webcast of the presentation is available here and can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 30 days following the presentation date.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndromes.
